253 related articles for article (PubMed ID: 25186025)
1. Management of cutaneous rosacea: emphasis on new medical therapies.
Del Rosso JQ
Expert Opin Pharmacother; 2014 Oct; 15(14):2029-38. PubMed ID: 25186025
[TBL] [Abstract][Full Text] [Related]
2. Rosacea: an update on medical therapies.
Chang BP; Kurian A; Barankin B
Skin Therapy Lett; 2014; 19(3):1-4. PubMed ID: 25188361
[TBL] [Abstract][Full Text] [Related]
3. Optimizing the use of topical brimonidine in rosacea management: panel recommendations.
Tanghetti EA; Jackson JM; Belasco KT; Friedrichs A; Hougier F; Johnson SM; Kerdel FA; Palceski D; Hong HC; Hinek A; Cadena MJ
J Drugs Dermatol; 2015 Jan; 14(1):33-40. PubMed ID: 25607906
[TBL] [Abstract][Full Text] [Related]
4. Ivermectin 1% (CD5024) for the treatment of rosacea.
Sahni DR; Feldman SR; Taylor SL
Expert Opin Pharmacother; 2018 Apr; 19(5):511-516. PubMed ID: 29544355
[TBL] [Abstract][Full Text] [Related]
5. Rosacea: update on management and emerging therapies.
Fallen RS; Gooderham M
Skin Therapy Lett; 2012 Dec; 17(10):1-4. PubMed ID: 23223767
[TBL] [Abstract][Full Text] [Related]
6. Facial Erythema of Rosacea - Aetiology, Different Pathophysiologies and Treatment Options.
Steinhoff M; Schmelz M; Schauber J
Acta Derm Venereol; 2016 Jun; 96(5):579-86. PubMed ID: 26714888
[TBL] [Abstract][Full Text] [Related]
7. Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 5: a guide on the management of rosacea.
Del Rosso JQ; Thiboutot D; Gallo R; Webster G; Tanghetti E; Eichenfield LF; Stein-Gold L; Berson D; Zaenglein A;
Cutis; 2014 Mar; 93(3):134-8. PubMed ID: 24738094
[TBL] [Abstract][Full Text] [Related]
8. Management of facial erythema of rosacea: what is the role of topical α-adrenergic receptor agonist therapy?
Del Rosso JQ
J Am Acad Dermatol; 2013 Dec; 69(6 Suppl 1):S44-56. PubMed ID: 24229637
[TBL] [Abstract][Full Text] [Related]
9. Rosacea Management: Update on general measures and topical treatment options.
Schaller M; Schöfer H; Homey B; Hofmann M; Gieler U; Lehmann P; Luger TA; Ruzicka T; Steinhoff M
J Dtsch Dermatol Ges; 2016 Dec; 14 Suppl 6():17-27. PubMed ID: 27869379
[TBL] [Abstract][Full Text] [Related]
10. Long-term safety and efficacy of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of a 1-year open-label study.
Moore A; Kempers S; Murakawa G; Weiss J; Tauscher A; Swinyer L; Liu H; Leoni M
J Drugs Dermatol; 2014 Jan; 13(1):56-61. PubMed ID: 24385120
[TBL] [Abstract][Full Text] [Related]
11. Treatment of Rosacea With Concomitant Use of Topical Ivermectin 1% Cream and Brimonidine 0.33% Gel: A Randomized, Vehicle-controlled Study.
Gold LS; Papp K; Lynde C; Lain E; Gooderham M; Johnson S; Kerrouche N
J Drugs Dermatol; 2017 Sep; 16(9):909-916. PubMed ID: 28915286
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double-blind, and vehicle-controlled pivotal studies.
Fowler J; Jackson M; Moore A; Jarratt M; Jones T; Meadows K; Steinhoff M; Rudisill D; Leoni M
J Drugs Dermatol; 2013 Jun; 12(6):650-6. PubMed ID: 23839181
[TBL] [Abstract][Full Text] [Related]
13. Oxymetazoline hydrochloride cream for facial erythema associated with rosacea.
Patel NU; Shukla S; Zaki J; Feldman SR
Expert Rev Clin Pharmacol; 2017 Oct; 10(10):1049-1054. PubMed ID: 28837365
[TBL] [Abstract][Full Text] [Related]
14. Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 1: a status report on the disease state, general measures, and adjunctive skin care.
Del Rosso JQ; Thiboutot D; Gallo R; Webster G; Tanghetti E; Eichenfield L; Stein-Gold L; Berson D; Zaenglein A
Cutis; 2013 Nov; 92(5):234-40. PubMed ID: 24343208
[TBL] [Abstract][Full Text] [Related]
15. Paradoxical Erythema Reaction of Long-term Topical Brimonidine Gel for the Treatment of Facial Erythema of Rosacea.
Lowe E; Lim S
J Drugs Dermatol; 2016 Jun; 15(6):763-5. PubMed ID: 27272086
[TBL] [Abstract][Full Text] [Related]
16. Emerging topical drugs for the treatment of rosacea.
Dall'Oglio F; Nasca MR; Micali G
Expert Opin Emerg Drugs; 2021 Mar; 26(1):27-38. PubMed ID: 33596752
[No Abstract] [Full Text] [Related]
17. Rationale for Use of Combination Therapy in Rosacea.
Stein Gold L; Baldwin H; Harper JC
J Drugs Dermatol; 2020 Oct; 19(10):929-934. PubMed ID: 33026776
[TBL] [Abstract][Full Text] [Related]
18. Medical Management of Facial Redness in Rosacea.
Cline A; McGregor SP; Feldman SR
Dermatol Clin; 2018 Apr; 36(2):151-159. PubMed ID: 29499798
[TBL] [Abstract][Full Text] [Related]
19. Role of Topical Oxymetazoline for Management of Erythematotelangiectatic Rosacea.
Hoover RM; Erramouspe J
Ann Pharmacother; 2018 Mar; 52(3):263-267. PubMed ID: 29094614
[TBL] [Abstract][Full Text] [Related]
20. Emerging therapies in rosacea.
Layton A; Thiboutot D
J Am Acad Dermatol; 2013 Dec; 69(6 Suppl 1):S57-65. PubMed ID: 24229638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
